This new program is designed to bring the science of quantitative modeling to our efforts to translate new tests and therapies from the laboratory into the clinic and to the community. Its ultimate purpose is to catalyze effective translational medicine through the rigorous application of quantitative models at each stage of the translational process within the Indiana CTSI. Implicit within this effort is the drive toward more personalized medicine using biomarkers that characterize disease severity and/or therapeutic response and particularly pharmacogenomics to target genetically identifiable response populations. We anticipate that the new models we develop in the laboratory, in the Clinical Research Center and in the community will be used to improve existing and future therapies by generating the data that enables targeting them to susceptible populations and even individual patients who are likely to achieve the most benefit with the least adversity from specific treatments. The program that we propose involves a full partnership with (and significant contribution of resources and expertise from) Eli Lilly and Company, based in Indianapolis, and the Indiana CTSI. Lilly is recognized within the pharmaceutical industry as a world leader in the area of pharmacokinetic/ pharmacodynamic modeling and in the application of these models to human disease. Since this activity involves the application of scientific approaches that requires skills not widely available, by necessity it has a significant training component. The discovery and training program that we propose will transform translational and clinical research by consistently forcing the consideration of quantitative models designed to allow the translation of discoveries from the bench to the bedside and then to the community. The program is truly innovative in that it will bring the new science of therapeutics and disease modeling to our translational efforts.